“It’s one of the most exciting study results I’ve seen in the past 15 years”
Simon Stebbings, Consultant Rheumatologist and Senior Research Professor, Otago University
Journal of Clinical Rheumatology
A double-blind, randomised, placebo-controlled clinical trial investigating the safety and efficacy of Arthrem® in patients with osteoarthritis of the hip or knee was conducted at Dunedin Hospital, University of Otago. The group of patients taking Arthrem® (at the recommended dose of 1 capsule twice daily) showed statistically significant improvements in pain and physical function over 12 weeks. Arthrem® at this dose was also well tolerated with no treatment-related side effects.
New Zealand Medical Journal
In an open-label extension study of the double blind, randomised, controlled clinical trial, Arthrem® was shown to be a safe and effective alternative for managing the symptoms of osteoarthritis over an extended period
Journal of Inflammation Research
Independent laboratory research helps explain why Arthrem® may relieve joint pain and stiffness. A paper published in The Journal of Inflammation Research shows that the primary ingredient of Arthrem® has potent anti-inflammatory activity in vitro.